Latest Kaiser Health News Stories
Congress is back in session, but covid diagnoses for Vice President Kamala Harris and two Democratic senators have temporarily left the Senate without a working majority to approve continued covid funding. Meanwhile, opponents of the Affordable Care Act have filed yet another lawsuit challenging a portion of the law, and we say goodbye to the late Sen. Orrin Hatch of Utah, who left a long legacy of health laws. Rachel Cohrs of STAT News, Anna Edney of Bloomberg News, and Rebecca Adams of KHN join KHN’s Julie Rovner to discuss these issues and more.
A Texas federal judge, who previously ruled the Affordable Care Act unconstitutional, has signaled his openness to ending the law’s popular coverage requirement for preventive services.
El Instituto Nacional del Cáncer lanzará un estudio que involucrará a unas 5,000 mujeres para evaluar si la autoprueba casera puede equivaler a la que realiza el médico en un consultorio.
The National Cancer Institute plans to launch a multisite study next year involving roughly 5,000 women to assess whether self-sampling at home for the human papillomavirus that causes cervical cancer is comparable to screening in a doctor’s office.
La investigación de KHN muestra que el dinero de la industria ha delineado políticas, a la opinión pública y a la atención al paciente en torno a las pruebas 3D.
Companies are aggressively touting 3D mammograms, although there’s no evidence they save lives.
Aunque muchas aseguradoras cubren PrEP, los costos por las pruebas adicionales que hay que realizarse pueden bloquear el acceso a esta terapia preventiva.
The U.S. Preventive Services Task Force recommended that people who are at high risk of contracting HIV take PrEP, a preventive treatment. The decision means most health plans will be required to cover the drugs without charging patients. But the recommendation doesn’t apply to the other clinical and lab services people need.
Health was a featured player in President Donald Trump’s 2019 State of the Union address. The president set goals to bring down prescription drug prices, end the HIV epidemic in the U.S. and cure childhood cancer, among other things. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Alice Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN senior correspondent Phil Galewitz about the current “Bill of the Month” feature.
Un estudio que analizó el consumo de esta dieta en 25,000 mujeres, por 12 años, comprobó sus virtudes y cómo actúa el factor preventivo.
New research not only confirms the heart health benefits of a Mediterranean-style diet, but also tracks these benefits over the long term.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.
And new study finds no reason to get routine vitamin D tests, researchers say.
Los investigadores definieron los males cardíacos graves como el índice combinado de ataques cardíacos, apoplejía y muertes relacionadas con el corazón.
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
On April 1, Medicare launched a major initiative — a diabetes prevention program for seniors and people with serious disabilities— that is available in only a few cities.
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
En Los Angeles, un centro que atiende a mujeres víctimas de abuso en el hogar tiene una oficina, y pronto un refugio, en el campus de un concurrido hospital.
Health care professionals increasingly collaborate with anti-abuse advocates to identify victims and ensure they get the help they need. One women’s center is opening a shelter on the campus of a large public hospital in Los Angeles.
The price for Pfizer’s Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.